<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594213</url>
  </required_header>
  <id_info>
    <org_study_id>M602011071</org_study_id>
    <nct_id>NCT04594213</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines</brief_title>
  <acronym>ULTRA I</acronym>
  <official_title>A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of NT 201 (active&#xD;
      ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined&#xD;
      treatment of wrinkles in the upper face (Upper Facial Lines [UFL]): Horizontal Forehead Lines&#xD;
      [HFL], Glabellar Frown Lines [GFL], and Lateral Canthal Lines [LCL]). It is a prospective,&#xD;
      randomized, double-blind, placebo-controlled, multicenter study with a placebo-control main&#xD;
      period (MP) followed by an open-label extension period (OLEX).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Glabella Frown Line (GFL) responders at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS - 5-point scale) will be used to identify responders</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Horizontal Forehead Lines (HFL) responders at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS - 5-point scale) will be used to identify responders</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Lateral Canthal Lines (LCL) responders at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS - 5-point scale) will be used to identify responders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a score of 0 (no) or 1 (mild) on MAS for GFL at maximum contraction as assessed by the investigator at post-baseline visits of MP</measure>
    <time_frame>Week 1, 4, 8, 12, and 16</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a score of 0 (no) or 1 (mild) on MAS for HFL at maximum contraction as assessed by the investigator at post-baseline visits of MP</measure>
    <time_frame>Week 1, 4, 8, 12, and 16</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a score of 0 (no) or 1 (mild) on MAS for both left and right LCL at maximum contraction as assessed by the investigator at post-baseline visits of MP</measure>
    <time_frame>Week 1, 4, 8, 12, and 16</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) as assessed by the subject at Day 30 of MP</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least one-grade improvement from baseline to Day 30 of MP on MAS for GFL at maximum contraction as assessed by the investigator</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least one-grade improvement from baseline to Day 30 of MP on MAS for HFL at maximum contraction as assessed by the investigator</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least one-grade improvement from baseline to Day 30 of MP on MAS for both left and right LCL at maximum contraction as assessed by the investigator</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) as assessed by the investigator at Day 30 of MP</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of related treatment-emergent adverse events (TEAEs) in the MP</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of related treatment-emergent adverse events (TEAEs) in the OLEX period</measure>
    <time_frame>Week 16 to 48</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)</condition>
  <arm_group>
    <arm_group_label>MP: NT 201 (incobotulinumtoxinA): UFL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP: NT201 (incobotulinumtoxinA): GFL/HFL; Placebo: LCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP: Placebo: UFL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OLEX: NT201 (incobotulinumtoxinA): UFL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT 201</intervention_name>
    <description>Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).</description>
    <arm_group_label>MP: NT 201 (incobotulinumtoxinA): UFL</arm_group_label>
    <arm_group_label>MP: NT201 (incobotulinumtoxinA): GFL/HFL; Placebo: LCL</arm_group_label>
    <arm_group_label>OLEX: NT201 (incobotulinumtoxinA): UFL</arm_group_label>
    <other_name>IncobotulinumtoxinA</other_name>
    <other_name>Xeomin</other_name>
    <other_name>Botulinum toxin type A (150 kiloDalton), free from complexing protein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).</description>
    <arm_group_label>MP: NT201 (incobotulinumtoxinA): GFL/HFL; Placebo: LCL</arm_group_label>
    <arm_group_label>MP: Placebo: UFL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients (male or female) 18 years of age or older.&#xD;
&#xD;
          -  Horizontal forehead lines [HFL], glabellar frown lines [GFL], and symmetrical lateral&#xD;
             canthal lines [LCL] of moderate (score 2) to severe (score 3) intensity at maximum&#xD;
             contraction as assessed by the investigator and subject according to Merz Aesthetics&#xD;
             Scales [MAS].&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with botulinum neurotoxin [BoNT] of any serotype in the face within&#xD;
             the last 12 months before injection.&#xD;
&#xD;
          -  Any facial cosmetic procedure within the last 12 months before baseline injection.&#xD;
&#xD;
          -  Previous treatment with any biodegradable filler in the face within the last 12 months&#xD;
             before injection.&#xD;
&#xD;
          -  Any previous insertion of permanent material in the face (regardless of the time&#xD;
             between previous treatment and this study).&#xD;
&#xD;
          -  Any medical condition that may put the subject at increased risk with exposure to&#xD;
             NT201.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Aesthetics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Clinical Testing Center of Beverly Hills, Merz Investigational Site #0010395</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steve Yoelin MD Medical Asscociates, Merz Investigational Site #0010435</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cosmetic Laser Dermatology, Merz Investigational Site #0010321</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AboutSkin Research, Merz Investigational Site #0010103</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology and Dermatologic Surgery, Merz Investigational Site #0010170</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical and Cosmetic Research, Merz Investigational Site #0010453</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven Fagien, Merz Investigation Site #0010449</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Cosmetic Dermatologic Surgery, Merz Investigational Site #0010105</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aesthetic Plastic Surgery Center, Merz Investigational Site #0010405</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kane Plastic Surgery, Merz Investigational Site #0010297</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Research Group, Merz Investigational Site #0010448</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center, Merz Investigational Site #0010097</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

